Cited by 110Multiple Myeloma Research and TreatmentsBone Metabolism and DiseasesBone health and treatments

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Immunocytochemistry reveals RANKL expression of myeloma cells

Open access

Sezer, Orhan, Heider, Ulrike, Jakob, Christian, Zavrski, Ivana, Eucker, Jan, Possinger, Kurt, Sers, Christine, Krenn, Veit·2002·Blood

DOI 10.1182/blood-2002-01-0148

Open this paper in CoChat — free account Open PDF

Abstract

Two highly interesting papers related to osteoclastic activation in multiple myeloma were published in the December 15 issue of Blood. [1][1],[2][2] These studies were related to the imbalance of 2 molecules involved in the regulation of bone resorption: receptor activator of NF-kappaB ligand (RANKL

Integrity signals

Registry

Crossref · 10.1182/blood-2002-01-0148

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 376
Blockade of adenosine diphosphate receptors P2Y12 and P2Y1 is required to inhibit platelet aggregation in whole blood under flow
Turner, N. A., Moake, J. L., & McIntire, L. V. (2001) · Blood · doi:10.1182/blood.v98.12.3340 · Cited by 146
Human bone marrow myeloma cells express RANKL.
Sezer, O., Heider, U., Jakob, C., Eucker, J., Possinger, K., & Roodman, G. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.353 · Cited by 104
Self-citation
Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer, O., Heider, U., Zavrski, I., & Possinger, K. (2001) · PubMed · Cited by 47
Self-citation
Immunohistochemical Study of Intermediate Filament Proteins on Routinely Processed, Celloidin-embedded Human Temporal Bone Sections by Using a New Technique for Antigen Retrieval
Shi, S., Tandon, A. K., Haussmann, R. R. M., Kalra, K. L., & Taylor, C. R. (1993) · Acta Oto-Laryngologica · doi:10.3109/00016489309135766 · Cited by 29

Show all 7 references

Research works printed but not linked: 1

Altamirano, 2000, RANKL is expressed in malignant multiple myeloma cell lines [abstract]., Blood., 96, 365a

Sorted by citations

Mechanisms of Bone Metastasis
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,752
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
Self-citation
The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
Farrugia, A. N., Atkins, G. J., To, L. B., Pan, B.-Q., Horvath, N., Kostakis, P., Findlay, D. M., Bardy, P., & Zannettino, A. C. W. (2003) · PubMed · Cited by 220
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N. S., Mitsiades, C. S., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
Bortezomib inhibits human osteoclastogenesis
von Metzler, I., Krebbel, H., Hecht, M., Manz, R., Fleissner, C., Mieth, M., Kaiser, M., Jakob, C., Sterz, J., Kleeberg, L., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404806 · Cited by 197
Self-citation
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Vanderkerken, K., Leenheer, E. D., Shipman, C. M., Asosingh, K., Willems, A., Camp, B. V., & Croucher, P. I. (2003) · PubMed · Cited by 188
Myeloma bone disease
Callander, N. S., & Roodman, G. D. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90020-4 · Cited by 166
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00692.x · Cited by 161
Self-citation
Pathogenesis of myeloma bone disease
Roodman, G. D. (2004) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2004.01.001 · Cited by 161
Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma
Kaiser, M., Mieth, M., Liebisch, P., Oberländer, R., Rademacher, J., Jakob, C., Kleeberg, L., Fleissner, C., Braendle, E., Peters, M., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01065.x · Cited by 158
Self-citation
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider, U., Langelotz, C., Jakob, C., Zavrski, I., Fleissner, C., Eucker, J., Possinger, K., Hofbauer, L. C., & Sezer, O. (2003) · PubMed · Cited by 156
Self-citation
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
Vallet, S., Raje, N. S., Ishitsuka, K., Hideshima, T., Podar, K., Chhetri, S., Pozzi, S., Breitkreutz, I., Kiziltepe, T., Yasui, H., et al. (2007) · Blood · doi:10.1182/blood-2007-05-093294 · Cited by 152
Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review
Bi, H., Chen, X., Gao, S., Yu, X., Xiao, J., Zhang, B., Liu, X., & Dai, M. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00234 · Cited by 146
Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling
Qiang, Y., Hu, B., Chen, Y., Zhong, Y., Shi, B., Barlogie, B., & Shaughnessy, J. D. (2009) · Blood · doi:10.1182/blood-2008-08-174300 · Cited by 141
Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis
Blair, J. M., Zhou, H., Seibel, M. J., & Dunstan, C. R. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0381 · Cited by 142
Multiple myeloma/hypercalcemia
Oyajobi, B. O. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2168 · Cited by 137
Neoplastic development in plasma cells
Potter, M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00061.x · Cited by 124
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Vallet, S., Palumbo, A. P., Raje, N. S., Boccadoro, M., & Anderson, K. C. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802005191 · Cited by 116
How B cells influence bone biology in health and disease
Horowitz, M. C., Fretz, J. A., & Lorenzo, J. (2010) · Bone · doi:10.1016/j.bone.2010.06.011 · Cited by 105
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function
Zavrski, I., Krebbel, H., Wildemann, B., Heider, U., Kaiser, M., Possinger, K., & Sezer, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.098 · Cited by 105
Self-citation
NF-??B in the pathogenesis and treatment of multiple myeloma
Li, Z., Chen, H., Campbell, R. A., Bonavida, B., & Berenson, J. R. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328302c7f4 · Cited by 97
An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R., & Croucher, P. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1287 · Cited by 82
Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets
Paul, A., Edwards, J., Pepper, C. J., & Mackay, S. P. (2018) · Cells · doi:10.3390/cells7100176 · Cited by 85
“Although normal plasma cells do not usually express RANKL, MM cells can gain the expression of this ligand [135] and interaction with RANK-expressing osteoclasts mediates their differentiation and activation through activation of NF-κB [136].”
Background
Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancer
Lu, T., Sathe, S. S., Swiatkowski, S. M., Hampole, C. V., & Stark, G. R. (2003) · Oncogene · doi:10.1038/sj.onc.1207332 · Cited by 80
“RANKL is highly expressed and involved in the tumorigenesis and metastasis of multiple myelomas (Sezer et al., 2002), giant cell tumors of the bone (Roux et al., 2002), prostate cancers (Brown et al., 2001), and neuroblastomas (Michigami et al., 2001).”
Background
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma
Ashcroft, A. J., Davies, F. E., & Morgan, G. J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01076-3 · Cited by 80
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease
Heider, U., Hofbauer, L. C., Zavrski, I., Kaiser, M., Jakob, C., & Sezer, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.146 · Cited by 69
Self-citation
Cellular Mechanisms of Multiple Myeloma Bone Disease
Oranger, A., Carbone, C., Izzo, M., & Grano, M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/289458 · Cited by 68
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma
Terpos, E., Politou, M., Szydlo, R., Nadal, E., Avery, S., Olavarría, E., Kanfer, E., Goldman, J. M., Apperley, J. F., & Rahemtulla, A. (2004) · Leukemia · doi:10.1038/sj.leu.2403423 · Cited by 66
The Immune Microenvironment of Myeloma
Noonan, K. A., & Borrello, I. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0086-3 · Cited by 63
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
Huang, H., & Hou, J. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.028 · Cited by 56
Multiple Myeloma and Bone: The Fatal InteractionPreprint
Marino, S., & Roodman, G. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031286 · Cited by 59
TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
Bai, H., Zhu, H., Yan, Q., Shen, X., Lu, X., Wang, J., Li, J., & Chen, L. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0280-8 · Cited by 54
Bone markers in multiple myeloma
Heider, U., Fleissner, C., Zavrski, I., Kaiser, M., Hecht, M., Jakob, C., & Sezer, O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.034 · Cited by 55
Self-citation
New insights into the pathophysiology and management of bone disease in multiple myeloma
Terpos, E., Politou, M., & Rahemtulla, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04712.x · Cited by 55
Unveiling Skeletal Fragility in Patients Diagnosed With MGUS: No Longer a Condition of Undetermined Significance?
Drake, M. T. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2387 · Cited by 53
The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression
Roux, S., & Mariette, X. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194310001593193 · Cited by 53
Mechanisms of multiple myeloma bone disease
Galson, D. L., Silbermann, R. W., & Roodman, G. D. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.135 · Cited by 50
Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma
Zangari, M., Yaccoby, S., Cavallo, F., Esseltine, D. L., & Tricot, G. J. K. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.047 · Cited by 50
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis
Haaber, J., Abildgaard, N., Knudsen, L. M., Dahl, I. M. S., Lodahl, M., Thomassen, M., Kerndrup, G. B., & Rasmussen, T. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06871.x · Cited by 49
“Some authors believe that MM PCs express RANKL (Sezer et al, 2002; Farrugia et al, 2003; Heider et al, 2003).”
Background
The role of markers of bone remodeling in multiple myeloma
Terpos, E., Politou, M., & Rahemtulla, A. (2004) · Blood Reviews · doi:10.1016/j.blre.2004.06.001 · Cited by 48
Targeting the bone microenvironment in multiple myeloma
Roodman, G. D. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0154-7 · Cited by 48
Novel targets for myeloma bone disease
Roodman, G. D. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1377 · Cited by 35
Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells
Okada, T., Akikusa, S., Okuno, H., & Kodaka, M. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1027362507683 · Cited by 37
“Although this finding differs from several studies showing RANKL expression by human primary myeloma cells [29, 30 ] and murine myeloma cell lines [31], it is consistent with others showing no RANKL expression in primary myeloma cells or myeloma cell lines [18, 19, 32], as well as with the finding that myeloma cell-me…”
BackgroundResult
Multiple myeloma-A painful disease of the bone marrow.
Díaz-DelCastillo, M., Chantry, A., Lawson, M., & Heegaard, A. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.10.006 · Cited by 33
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
Jakob, C., Zavrski, I., Heider, U., BOLLOW, M., Schulz, C., Fleissner, C., Eucker, J., Michael, R., Hamm, B., Possinger, K., et al. (2003) · PubMed · Cited by 36
Self-citation
Myeloma bone disease
Sezer, O. (2005) · Hematology · doi:10.1080/10245330512331389782 · Cited by 34
Self-citation
Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
Paton‐Hough, J., Tazzyman, S. J., Evans, H., Lath, D., Down, J. M., Green, A. C., Snowden, J. A., Chantry, A., & Lawson, M. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3606 · Cited by 34
“In most cases, osteoclast-stimulating factors including receptor activator of NF-kB ligand (RANKL),((5,6)) macrophage inflammatory protein 1,((7,8)) and various interleukins (IL-1b,((9)) IL-3,((10)) and IL-6((11))) are produced by myeloma cells or tumor-activated cells in the bone marrow microenvironment (BMME), causi…”
Background
Bone marrow adiposity and multiple myeloma
Morris, E. V., & Edwards, C. M. (2018) · Bone · doi:10.1016/j.bone.2018.03.011 · Cited by 32
“of molecules including MIP-1alpha RANKL, MMP-13 and Decoy receptor 3 (DcR3) [41-43].”
Background
Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma
Buckle, C., Leenheer, E. D., Lawson, M. A., Yong, K., Rabin, N. K., Perry, M., Vanderkerken, K., & Croucher, P. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041127 · Cited by 31
Expression of receptor activator of NF-?B ligand (RANKL) mRNA in human multiple myeloma cells
Heider, U., Zavrski, I., Jakob, C., B�ngeroth, K., Fleissner, C., Langelotz, C., Possinger, K., Hofbauer, L. C., Viereck, V., & Sezer, O. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0578-3 · Cited by 30
Self-citation
Evolution of AF6-RAS association and its implications in mixed-lineage leukemia
Smith, M. J., Ottoni, E., Ishiyama, N., Goudreault, M., Haman, A., Meyer, C., Tucholska, M., Gasmi-Seabrook, G. M. C., Menezes, S., Laister, R. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01326-5 · Cited by 28
OPG, RANKL, and RANK in Cancer Metastasis: Expression and Regulation
Brown, J. M., Zhang, J., & Keller, E. T. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-9129-4_7 · Cited by 28
Gallium nitrate in multiple myeloma: Prolonged survival in a cohort of patients with advanced-stage disease
Niesvizky, R. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00172-6 · Cited by 28
Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment
Locklin, R. M., Croucher, P. I., Russell, R. G. G., & Edwards, C. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404518 · Cited by 24
Evidence of a role for RANKL in the development of myeloma bone disease
DELEENHEER, E. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.011 · Cited by 26
“Flow cytometric and immunohistochemical studies have also demonstrated expression of RANKL on CD138þ myeloma cells isolated from the bone marrow of patients with multiple myeloma [42–45].”
Background
Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo
Ai, L., Sun, C., Wang, Y.-D., Zhang, L., Chu, Z., Qin, Y., Gao, F., Yan, H., Guo, T., Chen, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28116 · Cited by 23
Plasma Cell Tumors
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease
Forster, S., & Radpour, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.941437 · Cited by 21
Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-κB Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis
Shibata, H., Abe, M., Hiura, K., Wilde, J., Moriyama, K., Sano, T., Kitazoe, K.-I., Hashimoto, T., Ozaki, S., Wakatsuki, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0181 · Cited by 22
Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj, M. A., Owczarska, K., Sokołowska, U., Centkowski, P., Pogłód, R., & Kruk, B. (2005) · PubMed · Cited by 19
Pathogenesis and treatment of multiple myeloma bone disease
Hiasa, M., Harada, T., Tanaka, E. I., & Abe, M. (2021) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2021.08.006 · Cited by 18
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
Tibullo, D., Rosa, M. D., Giallongo, C., Cava, P. L., Parrinello, N. L., Romano, A., Conticello, C., Brundo, M. V., Saccone, S., Malaguarnera, L., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00226 · Cited by 18
Inhibition of Osteoclastogenesis by the RNA-Binding Protein QKI5: a Novel Approach to Protect from Bone Resorption
Rauwel, B., Degboé, Y., Diallo, K., Sayegh, S., Baron, M., Boyer, J., Constantin, A., Cantagrel, A. G., & Davignon, J. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3943 · Cited by 18
“It principally implicates a dysregulation of the immune system and stromal cells (rheumatoid arthritis [RA]((2,3)) or bone tumors((4))) along with an intense activation of immune cells leading to extremely fast bone resorption in osteoarticular infections and bone tumors.”
Background
Electrolyte Disorders in Cancer Patients
Latcha, S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2659-6_7 · Cited by 14
Role of the Microenvironment In Multiple Myeloma Bone Disease
Huston, A. J., & Roodman, G. D. (2006) · Future Oncology · doi:10.2217/14796694.2.3.371 · Cited by 14
“Recent evidence has suggested that small amounts of RANKL may be produced by MM cells [14,16], however, others have not detected RANKL production by MM cell lines or primary MM patient samples [15,17].”
Background
Bone disease in multiple myeloma.
Drake, M. T. (2009) · PubMed · Cited by 13
Death Receptors in Multiple Myeloma and Therapeutic Opportunities
Mollinedo, F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_25 · Cited by 12
The many roles of RANKL-RANK signaling in bone, breast and cancer
Schramek, D., & Penninger, J. M. (2011) · IBMS BoneKEy · doi:10.1138/20110512 · Cited by 11
Bisphosphonates in early multiple myeloma
Sezer, O., Jakob, C., Zavrski, I., Heider, U., Fleissner, C., & Freund, M. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00116.x · Cited by 10
Self-citation
NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma
Li, T., Qiu, D., Chen, Q., Yang, A., Chen, J., & Zeng, Z. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00905-1 · Cited by 9
“Consistent with previous studies, calcium oscillations can affect RANKL secretion in MM cells by regulating NFAT signaling [23, 24].”
Background
The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma
Kuliszkiewicz-Janus, M., Małecki, R., Żółtaszek, A., & Zastawny, M. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500232428 · Cited by 9
RANKL expression in a case of follicular lymphoma
Barcala, V., Ruybal, P., Rivello, H. G., Waldner, C., Ascione, A., & Mongini, C. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00067.x · Cited by 8
Pathophysiology of myeloma bone disease
Oyajobi, B. O., & Mundy, G. R. (2004) · CRC Press eBooks · doi:10.1201/b13347-9 · Cited by 8
Do Human Myeloma Cells Directly Produce the Receptor Activator of Nuclear Factor κB Ligand (RANKL) or Induce RANKL in the Bone Marrow Microenvironment?
Giuliani, N., Colla, S., Rizzoli, V., Barillé‐Nion, S., & Bataille, R. (2004) · Cancer Research · doi:10.1158/0008-5472.772.64.2 · Cited by 8
Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma
Chakraborty, C., & Mukherjee, S. (2022) · Current Oncology · doi:10.3390/curroncol29120749 · Cited by 7
The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment
Khalife, J., Sanchez, J. F., & Pichiorri, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.689538 · Cited by 6
Mechanisms of bone resorption in myeloma.
Roodman, G. D. (2003) · PubMed · Cited by 6
Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3
Lin, L., Chen, D., Xiang, Z., Pei, R., Zhang, P., Liu, X.-H., Du, X., & Lu, Y. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170584 · Cited by 5
The Malignant Hierarchy in Multiple Myeloma: Relationships between Malignant Cells and Bone Disease
Pilarski, L. M., Reiman, T., Pilarski, P. M., Orr, F. W., & Belch, A. R. (2004) · Cancer metastasis · doi:10.1007/978-1-4020-2036-0_7 · Cited by 5
Immunomodulation of Multiple Myeloma Bone Disease
Grano, M., Brunetti, G., & Colucci, S. C. (2009) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-009-9058-2 · Cited by 4
“The linkage between cells of immune system and bone loss is becoming more evident in MM and other bone loss-associated diseases through different mechanisms mainly due to the alteration of RANKL/ OPG axis [12, 42–52].”
BackgroundResult
Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cells
Ito, M., Amizuka, N., Tanaka, S., Funatsu-Ozawa, Y., Kenmotsu, S., Oda, K., Nakajima, T., & Ozawa, H. (2003) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0429-3 · Cited by 4
Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Catley, L. P., & Anderson, K. C. (2003) · doi:10.1002/9780470987070.ch92 · Cited by 3
Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone Disease
Grano, M., Brunetti, G., & Colucci, S. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00006-2 · Cited by 3
Contribution of osteoclasts to the bone–tumor niche
Edwards, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00005-4 · Cited by 2
Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells.
Heider, U., Zavrski, I., Jakob, C., Fleissner, C., & Sezer, O. (2004) · PubMed · Cited by 2
Self-citation
Role of The Osteoclast in Cancer
Green, A. C., Andrews, R. E., & Lawson, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11245-0 · Cited by 2
Osteoclasts: Potential Target for Blocking Microenvironmental Support of Myeloma
Galson, D. L., D'Souza, S. S., & Roodman, G. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_9 · Cited by 1
Évaluation des réponses cellulaires et tissulaires précoces induites par des implants sous-chondraux et présolidifiés composés de chitosane/sang dans un modèle ostéochondral
Lafantaisie-Favreau, C.-H. (2011) · PolyPublie (École Polytechnique de Montréal) · Cited by 1
RANKL: Targeting bone and cancer to treat skeletal complications of malignancy
Crook, M. K., & Guise, T. A. (2009) · IBMS BoneKEy · doi:10.1138/20090396 · Cited by 1
OPG, RANK and RANKL in Bone Metastasis and Cancer-Associated Osteolysis
Kostenuik, P. J. (2004) · Cancer metastasis · doi:10.1007/978-1-4020-2036-0_11 · Cited by 1
Myeloma Bone Disease
Huston, A. J., & Roodman, G. D. (2007) · Translational medicine series · doi:10.3109/9781420045116.003 · Cited by 1
Osteolyse beim Multiplen Myelom : Untersuchungen am Zellmodell
Bergmann, M., & Lorenzen, J. (2005) · RWTH Publications (RWTH Aachen)
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21
Pathophysiology of Bone Disease in Multiple Myeloma
Mark, T. M., & Pearse, R. N. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_27
Defining Key Molecules in a Myeloma Cell Niche
Paton‐Hough, J. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
T Cells in Patients with B-cell Chronic Lymphocytic Leukemia (B-CLL) and Multiple Myeloma (MM) An Immunological Study
Kiaii, S. (2007) · Figshare
The RANKL system and the development of tumor-induced bone disease: lessons from pre-clinical models.
Croucher, P. I. (2004) · PubMed
Interaktionen von Myelomzellen mit Osteoklasten und Osteoblasten und Einfluss von Proteasominhibitoren auf den Knochenstoffwechsel bei Patienten mit multiplem Myelom
THIEL, E. (2010)

Authors: Sezer, O., Heider, U., Jakob, C., Zavrski, I., Eucker, J., Possinger, K., Sers, C., & Krenn, V.
Affiliations: Charité – Universitätsmedizin Berlin (DE)
Corresponding author: Sezer, Orhan
Heider, Ulrike
Jakob, Christian
Zavrski, Ivana
Eucker, Jan
Possinger, Kurt
Sers, Christine
Krenn, Veit
ORCID: Sezer, Orhan
Jakob, Christian
Eucker, Jan
Sers, Christine
Venue: Blood
Publisher: American Society of Hematology
Published: 2002-06-15
Volume: 99
Issue: 12
Pages: 4646-4647
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2002-01-0148
OpenAlex: W2020103166
Cited by: 110
References: 7
Citations by year: 2022: 5 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 5 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 3
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: RANKL, multiple myeloma, myeloma cells, osteoclast activation, bone resorption, osteolytic lesions, NF-κB signaling
MeSH terms: Bone Marrow Cells, Carrier Proteins, Flow Cytometry, Humans, Immunohistochemistry, Membrane Glycoproteins, Multiple Myeloma, Neoplasm Proteins, Osteolysis, Plasma Cells, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunocytochemistry reveals RANKL expression of myeloma cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks